Circulating concentrations of glucagon-like peptide 1, glucose-dependent insulinotropic peptide, peptide YY, and insulin in client-owned lean, overweight, and diabetic cats

被引:11
|
作者
McMillan, C. J. [1 ]
Zapata, R. C. [2 ]
Chelikani, P. K. [2 ]
Snead, E. C. R. [3 ]
Cosford, K. [4 ]
机构
[1] Univ Calgary Vet Med, Dept Vet Clin & Diagnost Sci, Calgary, AB, Canada
[2] Univ Calgary Vet Med, Dept Prod Anim Hlth, Calgary, AB, Canada
[3] Univ Saskatchewan, Western Coll Vet Med, Dept Small Anim Clin Sci, Saskatoon, SK S7N 0W0, Canada
[4] Western Vet Specialists & Emergency Ctr, Calgary, AB, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
Feline; Diabetes; Enteroendocrine hormone; BODY CONDITION SCORE; RECEPTOR EXPRESSION; INCRETIN HORMONES; OBESE SUBJECTS; HEALTHY CATS; ORAL GLUCOSE; MIXED MEAL; L-CELLS; SECRETION; GLP-1;
D O I
10.1016/j.domaniend.2015.10.001
中图分类号
S8 [畜牧、 动物医学、狩猎、蚕、蜂];
学科分类号
0905 ;
摘要
Our objectives were to measure plasma concentrations of glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and peptide YY (PYY) in client-owned newly diagnosed diabetic cats and nondiabetic lean or overweight cats and to determine whether circulating concentrations of these hormones differed between study groups and if they increased postprandially as seen in other species. A total of 31 cats were recruited and placed into 1 of 3 study groups: lean (body condition score 4-5 on a scale of 1-9; n = 10), overweight (body condition score 6-8; n = 11), or diabetic (n = 10). Diabetics were newly diagnosed and had not had prior insulin therapy. Preprandial (fasting) and postprandial (60 min after meal) plasma hormone and glucose concentrations were measured at baseline and 2 and 4 wk. All cats were exclusively fed a commercially available high-protein and low-carbohydrate diet commonly prescribed to feline diabetic patients for 2 wk before the 2-wk assessment and continued through the 4-wk assessment. Results showed that plasma concentrations of GLP-1, GIP, PYY, and insulin increased in general after a meal in all study groups. Plasma PYY concentrations did not differ (P > 0.10) between study groups. Diabetics had greater plasma concentrations of GLP-1 and GIP compared with the other study groups at baseline (P < 0.05), and greater preprandial and postprandial GLP-1 concentrations than lean cats at 2 and 4 wk (P < 0.05). Preprandial plasma GIP concentrations were greater in diabetics than obese and lean (P < 0.05) cats at week 4. Postprandial plasma GIP concentrations in diabetics were greater than lean (P < 0.05) at week 2 and obese and lean cats (P < 0.05) at week 4. Together, our findings suggest that diabetic status is an important determinant of circulating concentrations of GLP-1 and GIP, but not PYY, in cats. The role of GLP-1, GIP, and PYY in the pathophysiology of feline obesity and diabetes remains to be determined. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:85 / 94
页数:10
相关论文
共 50 条
  • [41] Dissociated effects of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 on β-cell secretion and insulin clearance in mice
    Pacini, Giovanni
    Thomaseth, Karl
    Ahren, Bo
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2010, 59 (07): : 988 - 992
  • [42] Glucose-dependent insulinotropic peptide (GIP)-stimulated insulin secretion is impaired in GK-rats, but can be restored by glucagon-like peptide-1 (GLP-1)
    De Heer, J
    Hoy, MK
    Holst, JJ
    DIABETES, 2005, 54 : A632 - A632
  • [43] EFFECTS OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE AND GLUCAGON-LIKE PEPTIDE-I-(7-36) ON INSULIN-SECRETION
    JIA, X
    BROWN, JC
    MA, P
    PEDERSON, RA
    MCINTOSH, CHS
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1995, 268 (04): : E645 - E651
  • [44] INSULIN-SECRETION AND PLASMA-LEVELS OF GLUCOSE-DEPENDENT INSULINOTROPIC PEPTIDE AND GLUCAGON-LIKE PEPTIDE-1 [7-36 AMIDE] AFTER ORAL GLUCOSE IN CIRRHOSIS
    KRUSZYNSKA, YT
    GHATEI, MA
    BLOOM, SR
    MCINTYRE, N
    HEPATOLOGY, 1995, 21 (04) : 933 - 941
  • [45] The Effect of Exogenous Glucose-Dependent Insulinotropic Polypeptide in Combination With Glucagon-Like Peptide-1 on Glycemia in the Critically Ill
    Lee, Michael Y.
    Fraser, Jonathan D.
    Chapman, Marianne J.
    Sundararajan, Krishnaswamy
    Umapathysivam, Mahesh M.
    Summers, Matthew J.
    Zaknic, Antony V.
    Rayner, Christopher K.
    Meier, Juris J.
    Horowitz, Michael
    Deane, Adam M.
    DIABETES CARE, 2013, 36 (10) : 3333 - 3336
  • [46] Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals
    Gasbjerg, Laerke S.
    Helsted, Mads M.
    Hartmann, Bolette
    Jensen, Mette H.
    Gabe, Maria B. N.
    Sparre-Ulrich, Alexander H.
    Veedfald, Simon
    Stensen, Signe
    Lanng, Amalie R.
    Bergmann, Natasha C.
    Christensen, Mikkel B.
    Vilsboll, Tina
    Holst, Jens J.
    Rosenkilde, Mette M.
    Knop, Filip K.
    DIABETES, 2019, 68 (05) : 906 - 917
  • [47] Nutrient-induced secretion and metabolic effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1
    Knapper, JME
    Morgan, LM
    Fletcher, JM
    PROCEEDINGS OF THE NUTRITION SOCIETY, 1996, 55 (1B) : 291 - 305
  • [48] Constitutional thinness and lean anorexia nervosa display opposite concentrations of peptide YY, glucagon-like peptide 1, ghrelin, and leptin
    Germain, Natacha
    Galusca, Bogdan
    Le Roux, Carel W.
    Bossu, Cecile
    Ghatei, Mohammad A.
    Lang, Francois
    Bloom, Stephen R.
    Estour, Bruno
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 2007, 85 (04): : 967 - 971
  • [49] Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer's and Parkinson's diseases
    Holscher, Christian
    FRONTIERS IN SYNAPTIC NEUROSCIENCE, 2022, 14
  • [50] Cholecystokinin, glucose dependent insulinotropic peptide and glucagon-like peptide 1 secretion in children with anorexia nervosa and simple obesity
    Tomasik, PJ
    Sztefko, K
    Starzyk, J
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2004, 17 (12): : 1623 - 1631